Eli Lilly Spends Nearly $4 Billion to Enter the Vaccine Market
Eli Lilly is buying 3 vaccine firms for up to $4B to expand beyond diabetes and obesity into infectious disease vaccines.
NOTRELOAD AI
Elbit Systems Beats Q1 Estimates and Wins $1.4 Billion European Military Modernization Contract
Elbit Systems beat Q1 2026 estimates and won $1.4B European deal, boosting sales, profits and future backlog.
Jefferies Sees Hemlibra-Like Potential in Hemab Therapeutics, Starts Coverage with Buy Rating
Hemab targets rare bleeding diseases with new treatments, strong cash, and big growth potential, with analysts seeing ~50% upside.
Tectonic Therapeutics Gets Strong Buy Upgrade: Two Potential Blockbusters in Focus
Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.
Curium Makes $7 Billion Takeover Offer for Lantheus Holdings
Lantheus is in talks to be bought by Curium for about $7B. No deal yet. Stock rose. Deal would be big in nuclear medicine.
Gilead’s Hepcludex Becomes First Approved Treatment for Chronic Hepatitis Delta
FDA approves first HDV drug Hepcludex in US after prior rejection; lowers virus, but needs monitoring for safety risks.